ストックスクリーナーアプリを入手
0.7101
0.17%
0.0012
アフターアワーズ：
.71
-0.000100
-0.01%
前日終値:
$0.7089
開ける：
$0.7295
24時間の取引高:
31,719
Relative Volume:
0.35
時価総額：
$66.03M
収益：
$5.61M
当期純損益:
$-42.51M
株価収益率:
-1.5238
EPS:
-0.466
ネットキャッシュフロー:
$-16.86M
1週間 パフォーマンス:
+9.23%
1か月 パフォーマンス:
-8.96%
6か月 パフォーマンス:
-38.25%
1年 パフォーマンス:
-84.92%
1日の値動き範囲:
$0.68
$0.7298
1週間の範囲:
$0.6612
$0.735
52週間の値動き範囲:
$0.4912
$4.8019
Citius Oncology Inc Stock (CTOR) Company Profile
Compare CTOR vs TAK, HLN, TEVA, ZTS, UTHR
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CTOR
Citius Oncology Inc
|
0.7101 | 65.91M | 5.61M | -42.51M | -16.86M | -0.466 |
TAK
Takeda Pharmaceutical Co Adr
|
16.96 | 53.37B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.84 | 42.80B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.65 | 41.09B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
76.29 | 31.62B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
563.70 | 23.23B | 3.17B | 1.29B | 1.01B | 27.09 |
Citius Oncology Inc Stock (CTOR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-09-23 | アップグレード | Maxim Group | Hold → Buy |
| 2024-11-27 | 開始されました | Maxim Group | Buy |
Citius Oncology Inc (CTOR) 最新ニュース
CTOR Q1 2026 Earnings: Significant EPS Miss Signals Ongoing Development-Stage ChallengesEarnings Yield Analysis - dars.gov.et
Enterprise value to EBITDA forward of Citius Oncology, Inc. – NASDAQ:CTOR - TradingView
Price to sales forward of Citius Oncology, Inc. – NASDAQ:CTOR - TradingView
Citius Oncology, Inc. Actuals & Estimates (NASDAQ:CTOR) - TradingView
Citius Oncology, Inc. Actuals & Estimates (BOATS:CTOR) - TradingView
Price to earnings forward of Citius Oncology, Inc. – NASDAQ:CTOR - TradingView
Citius Oncology Inc (CTOR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Price to book forward of Citius Oncology, Inc. – NASDAQ:CTOR - TradingView
CTOR Forecast — Price Target — Prediction for 2027 - TradingView
Enterprise value to revenue forward of Citius Oncology, Inc. – NASDAQ:CTOR - TradingView
CTOR Q1 2026 Earnings: Wider-Than-Expected Loss Alarms InvestorsEarnings Per Share - dars.gov.et
Citius Oncology Inc (CTOR) Valuation: PE, PB & Fair Value Analysis - TradingKey
Citius Oncology Inc (CTOR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
CITIUS ONCOLOGY INC (CTOR) Stock Chart - ChartMill
Citius Oncology Inc (CTOR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Citius Oncology Inc (CTOR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Citius Oncology Inc (CTOR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Citius Oncology Inc (CTOR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Citius Oncology Inc (CTOR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Citius Oncology Inc (CTOR) Institutional Confidence - TradingKey
CTOR Q1 2026 Earnings: Deep EPS Miss Highlights Pre‑Revenue ChallengesEstimate Revision Count - newsline.com
Citius Oncology Inc. (CTOR) Gains 6% as Buyers Defend Key SupportSentiment Divergence - newsline.com
CTOR Q1 2026 Earnings: Significant EPS Miss Highlights Continued Investment in PipelineRevenue Surprise History - newsline.com
Citius Oncology (CTOR) Edges Higher as Stock Hovers Near SupportMcClellan Summation - newsline.com
CTXR News | CITIUS PHARMACEUTICALS INC (NASDAQ:CTXR) - ChartMill
[EFFECT] CITIUS ONCOLOGY, INC. SEC Filing - Stock Titan
Citius Oncology (CTOR) stake updated by majority holder Citius Pharma - Stock Titan
Citius Oncology, Inc. Financial Disclosures & SEC Filings - TradingView
[EFFECT] Citius Pharmaceuticals, Inc. SEC Filing - Stock Titan
Citius Oncology Reports Promising Phase 1 Results for LYMPHIR Plus Pembrolizumab in Recurrent Gynecologic Cancers at ASCO 2026 123 - Minichart
Citius Oncology Highlights Promising Phase 1 Results for LYMPHIR® Plus Pembrolizumab in Recurrent Gynecologic Cancers at ASCO 2026 123 - Minichart
Citius Highlights LYMPHIR Combo Data in Gynecologic Cancers - TipRanks
Citius Oncology (CTOR) registers 6.8M warrant shares; highlights Phase 1 LYMPHIR data - Stock Titan
Citius Oncology (NASDAQ: CTOR) highlights Phase 1 LYMPHIR plus pembrolizumab results - Stock Titan
Citius Oncology Highlights Phase 1 Data in an Investigator-Initi - GuruFocus
Citius Oncology (CTXR) Presents Promising Data on LYMPHIR for Gy - GuruFocus
Citius Oncology presents study data on LYMPHIR combination By Investing.com - Investing.com Australia
Citius Oncology presents study data on LYMPHIR combination - Investing.com
Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR® (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies - PR Newswire
Citius Oncology (NASDAQ: CTOR) clears potential $25M loan conversions and large warrants - Stock Titan
Citius Oncology (Nasdaq: CTOR) registers 32.9M shares tied to warrants and loan conversion - Stock Titan
CTOR Q1 2026 Earnings: Significant EPS Miss Amid Pre-Revenue PhaseBook Value Growth - thelegaladvocate.com
Number of shareholders of Citius Oncology, Inc. – NASDAQ:CTOR - TradingView
Citius Oncology Announces Presentation of LYMPHIR® Phase 1 Combi - GuruFocus
Citius Oncology study combining LYMPHIR with pembrolizumab selected for ASCO presentation - Investing.com Nigeria
Citius Oncology study combining LYMPHIR with pembrolizumab selected for ASCO presentation By Investing.com - Investing.com South Africa
CTXRCitius Pharmaceuticals Inc Stock Price and Quote - Finviz
CTORCitius Oncology Inc Stock Price and Quote - Finviz
Citius Oncology Announces Presentation of LYMPHIR® Phase 1 Combination Study Data at the 2026 American Society of Clinical Oncology Annual Meeting - PR Newswire
Citius Oncology Q1 2026 Earnings: Wide EPS Miss Highlights Pre-Revenue ChallengesManagement Guidance Update - newsline.com
Is Citius Pharmaceuticals, Inc. (CTXR) among the Best Rated Penny Stocks to Buy According to Wall Street Analysts? - Yahoo Finance
Citius Oncology Inc (CTOR) 財務データ
収益
当期純利益
現金流量
EPS
0.17%
1.98%
大文字化:
|
ボリューム (24 時間):